Filing Flows › 13F managers › Alphabet
Alphabet: 13F portfolio Q2 2026 and what copying it returned
Alphabet's 13F for the quarter ended 2026-06-30 (filed Aug 7, 2026): 28 common-share positions, $99.1B reported. Copying each 13F the day after it was filed returned +204.0% from Nov 17, 2022 to Nov 6, 2026, against +85.9% for SPY.
Copying the 13F
Each 13F bought at the close of the first trading day after it was filed and held, drifting, until the next one; value-weighted over the common-share positions with a price (88.0% of the portfolio on average); 16 filings since Nov 15, 2022. Price returns for the clone and SPY alike (no dividends, no costs). A 13F lists only US long positions at quarter end, reported up to 45 days later.
Largest holdings (2026-06-30)
| Ticker | Company | Weight | Value | Change in the quarter |
|---|---|---|---|---|
| SPCX | Space Exploration Technologies | 95.0% | $94.2B | new |
| PL | Planet Labs PBC | 1.2% | $1.2B | unchanged |
| ASTS | AST SpaceMobile | 0.8% | $795M | unchanged |
| CME | CME Group | 0.8% | $769M | unchanged |
| ARM | Arm Holdings | 0.7% | $695M | unchanged |
| RVMD | Revolution Medicines | 0.6% | $552M | -10.5% |
| FRSH | Freshworks | 0.2% | $164M | unchanged |
| PBLS | Parabilis Medicines | 0.1% | $135M | new |
| TEM | Tempus AI | 0.1% | $89.9M | unchanged |
| GTLB | Gitlab | 0.1% | $83.2M | unchanged |
| PATH | UiPath | 0.1% | $76.5M | unchanged |
| LIFE | Ethos Technologies | 0.1% | $65.7M | -3.9% |
| PRME | Prime Medicine | 0.1% | $61.1M | unchanged |
| FRVO | Fervo Energy | 0.1% | $51.5M | new |
| PAYP | PayPay | 0.1% | $44.8M | unchanged |
| MAZE | Maze Therapeutics | 0.0% | $41.4M | unchanged |
| RLAY | Relay Therapeutics | 0.0% | $26.4M | -9.9% |
| BBOT | BridgeBio Oncology Therapeutics | 0.0% | $21.5M | unchanged |
| OSCR | Oscar Health | 0.0% | $13.7M | unchanged |
| BEAM | Beam Therapeutics | 0.0% | $11.0M | unchanged |
| VERA | Vera Therapeutics | 0.0% | $10.4M | unchanged |
| SANA | Sana Biotechnology | 0.0% | $9.8M | unchanged |
| GLUE | Monte Rosa Therapeutics | 0.0% | $9.0M | -45.6% |
| LYEL | Lyell Immunopharma | 0.0% | $4.1M | unchanged |
| FIG | Figma | 0.0% | $3.9M | unchanged |
Biggest adds
- SPCX new
- PBLS new
- FRVO new
Biggest cuts
- TNYA exit
- GLUE -45.6%
- RVMD -10.5%
- RLAY -9.9%
- LIFE -3.9%
Track record
Of 77 position changes scored in 77 separate decisions, 50.6% were on the right side of SPY over the next three months (Disclosures → Smart money).
Open in Disclosures → every quarter, the clone month by month, the smart-money record
Source: SEC Form 13F-HR, filer CIK 1652044. Not investment advice.